— Know what they know.
Not Investment Advice
Also trades as: 0HNC.L (LSE) · $vol 0M · BM8.F (FSX) · $vol 0M · BM8.DE (XETRA) · $vol 0M

BMRN NASDAQ

BioMarin Pharmaceutical Inc.
1W: -1.9% 1M: -6.9% 3M: -9.8% YTD: -6.9% 1Y: +1.6% 3Y: -32.6% 5Y: -25.3%
$55.35
-0.40 (-0.72%)
 
Weekly Expected Move ±3.9%
$52 $54 $56 $58 $60
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 38 · $10.7B mcap · 193M float · 1.09% daily turnover · Short 64% of daily vol
Credit Risk of going bust: lower than 58% of companies Debt: 28.2% of company value Bonds: $170.1M held by 149 funds, 129 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.66 (down 97%), BioMarin Pharmaceutical Inc. would be worth roughly what it owes.
Total debt $4.20B against a stock market value of $10.71B.
Distance to default 5.92 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.42B (short-term plus half of long-term), stock volatility 34.6%; Altman Z'' 2.74. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

📊 Key Metrics

TTM
$3B
Revenue
+11.2% YoY
$73M
Net Income
-88.9% YoY
$738M
Free Cash Flow
+6.8% YoY
79.5%
Gross Margin
11.2%
Op. Margin
4.5%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE1.2%
ROA0.8%
ROIC1.4%

Valuation

P/E145.7
P/B1.7
EV/EBITDA37.4

Leverage

Debt/Equity0.66
Current Ratio2.39
Interest Cov.2.8x

Quality Scores

Piotroski F4/9
Altman Z1.86
Beneish M-2.26

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms